your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com
Uptodate Reference Title
Approach to increasing the platelet count in ITP
Approach to increasing the platelet count in ITP
These platelet count thresholds are intended as a guide; some individuals with a platelet count <20,000 to 30,000/microL may reasonably choose not to receive treatment, and some individuals with additional bleeding risk factors may choose to receive treatment at higher platelet counts (up to 50,000/microL). We generally prefer glucocorticoids for initial therapy; we reserve IVIG (or anti-D) for those who have a contraindication to or intolerance of glucocorticoids or who require a more rapid increase in platelet count. Refer to a separate algorithm for treatment of bleeding. Refer to UpToDate for management of comorbidities, the importance of addressing other bleeding risk factors, decision-making between different therapies, and dosing and administration of specific medications.
ITP: immune thrombocytopenia; IVIG: intravenous immune globulin; TPO: thrombopoietin. * Many patients with platelet counts <20,000 to 30,000/microL do not require treatment. ¶ The interval for rechecking the platelet count is individualized based on the patient's clinical status, typically ranging from a few days to a week. Responses to glucocorticoids typically occur within a few days (range, 2 to 14 days); responses to IVIG (or anti-D) can occur within 1 to 3 days. Δ Splenectomy is generally deferred for at least 12 months after diagnosis (if possible), in case a spontaneous remission occurs. ◊ Other treatments include fostamatinib, danazol, other immunosuppressive agents, or combination therapy. § The risk of adverse drug effects must be balanced against the benefit of raising the platelet count in an asymptomatic patient (refer to UpToDate for discussion).
